Clinical trial shows 28% improvement in progression-free survival for glioblastoma patients — Evidence Review

A new clinical trial from the University of Calgary found that adding high-dose vitamin B3 (niacin) to standard glioblastoma care may improve short-term outcomes, with preliminary results showing a 28% increase in progression-free survival at six months. Related research on vitamins and brain cancer aligns with these findings, generally supporting the exploration of vitamins as adjuncts in cancer therapy, though evidence remains mixed and further study is needed.

• Several studies have highlighted the potential role of vitamins—including D, C, and E—in reducing cancer risk, influencing tumor progression, and supporting immune function, with some evidence suggesting improved outcomes in brain cancer patients when certain vitamins are used as adjuncts 1 3 4 5.
• However, the benefit of vitamin supplementation in brain cancers is not universally accepted; some studies report no significant association between multivitamin use and survival, while others emphasize the need for more rigorous clinical trials to establish efficacy and safety 3 11.
• The current study builds on previous laboratory and early clinical research, demonstrating that immune-modulating and antioxidant effects of vitamins may enhance standard treatments in aggressive brain cancers, though careful monitoring for side effects is essential 4 5 15.

Study Overview and Key Findings

Glioblastoma remains one of the most aggressive and treatment-resistant forms of brain cancer, with limited improvements in survival over the past two decades. Standard therapies—surgery, radiation, and chemotherapy—rarely prevent recurrence. This context underscores the significance of research into adjunctive strategies that could enhance patient outcomes. The new study investigates whether high-dose, controlled-release vitamin B3 (niacin) can boost immune function and improve the effectiveness of existing treatments in newly diagnosed glioblastoma patients, a question of particular importance given the disease’s poor prognosis and the urgent need for new therapeutic options.

Property	Value
Study Year	2025
Organization	University of Calgary, Hotchkiss Brain Institute, Arnie Charbonneau Cancer Institute
Journal Name	Journal of Neuro-Oncology
Authors	Gloria Roldan Urgoiti, Paula de Robles, Roger Y. Tsang, Morgan Willson, Sunita Ghosh, Muhammad Faruqi, Gerald Lim, Shaun Loewen, Robert Nordal, Gregory Cairncross, Catriona Leckie, Candice C. Poon, V. Wee Yong
Population	Patients with newly diagnosed glioblastoma
Sample Size	24 patients
Methods	Randomized Controlled Trial (RCT)
Outcome	Progression-free survival at six months
Results	82% had no disease progression at six months, a 28% improvement

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant studies:

1. vitamin brain cancer progression
2. aggressive brain cancer treatment outcomes
3. vitamin efficacy glioblastoma survival rates

Topic	Key Findings
Do vitamins influence cancer risk, progression, or survival outcomes?	- Vitamin D, C, and E supplementation may reduce cancer risk and improve prognosis, but evidence is mixed and dependent on specific populations and dosages 1 3 4 5. - In brain tumors, higher vitamin D receptor expression and certain vitamin supplements (e.g., vitamin D) have been associated with improved survival, though multivitamin use shows no clear mortality benefit in glioblastoma 11 12.
Can antioxidants or vitamins enhance standard brain cancer therapies?	- Antioxidant vitamins (C, E) may boost the efficacy of chemotherapy agents and promote cancer cell death, including in glioblastoma models 2 15. - Combining vitamin C with novel therapies (e.g., plasma-conditioned media) or standard drugs (methotrexate) can enhance anti-tumor effects in glioblastoma cells and animal models 13 15.
What are the challenges and current approaches in glioblastoma care?	- Standard care for glioblastoma includes surgery, chemoradiotherapy, and maintenance chemotherapy, with ongoing trials for adjunctive therapies such as immunotherapy and Tumor Treating Fields 6 8 10. - Resistance to standard treatments and the aggressive nature of glioblastoma create an urgent need for novel approaches, including immune modulation and targeted therapies 6 8 10.
Are there risks or limitations to vitamin supplementation in brain cancer patients?	- High-dose vitamins may cause side effects, and evidence for routine supplementation in glioblastoma is insufficient; benefits are potentially context-dependent and require careful monitoring 3 4 5 11. - Some studies suggest no mortality association with multivitamin use, while other individual supplements (e.g., vitamin D) show trends toward reduced mortality, though findings are not always statistically significant after adjustment for confounders 11.

Do vitamins influence cancer risk, progression, or survival outcomes?

The literature suggests that certain vitamins, particularly D, C, and E, may play a role in reducing cancer risk, modulating disease progression, or improving survival outcomes. However, the magnitude and consistency of these effects remain uncertain, especially in brain cancers. The current study’s finding that vitamin B3 might improve progression-free survival adds to ongoing research exploring vitamins as potential adjuncts in cancer therapy 1 3 4 5.

• Vitamin D deficiency is linked to increased cancer risk, and supplementation may improve outcomes, but randomized trials have yet to provide conclusive evidence 1.
• In glioblastoma, higher vitamin D receptor expression has been associated with improved survival, supporting a possible role for vitamin D pathways in disease progression 12.
• Observational studies have shown no clear mortality benefit from multivitamin use in glioblastoma, though select supplements, such as vitamin D, may have modest benefits 11.
• The evidence base for vitamins in cancer is mixed, necessitating further controlled studies to clarify therapeutic potential 3 4 11.

Can antioxidants or vitamins enhance standard brain cancer therapies?

Several experimental and preclinical studies indicate that antioxidant vitamins can augment conventional cancer treatments by promoting tumor cell death and enhancing chemotherapy efficacy. The new niacin study aligns with this trend by investigating a vitamin’s role in restoring immune function alongside standard care 2 13 15.

• Vitamin C and E, while not cytotoxic alone, can enhance the anticancer effects of low-dose chemotherapy in glioblastoma cell models, working via caspase-3-mediated cell death pathways 15.
• Combination strategies, such as vitamin C with plasma-conditioned media, have shown synergistic effects in reducing glioblastoma cell viability and promoting apoptosis in animal models 13.
• High pharmacological doses of vitamin C may inhibit cancer transformation by inducing DNA damage selectively in tumor cells and activating immune responses 2.
• These findings support the rationale for clinical trials investigating vitamin-based adjuncts in aggressive brain cancers, though clinical translation remains in early stages 2 13 15.

What are the challenges and current approaches in glioblastoma care?

Glioblastoma is characterized by rapid recurrence, resistance to therapy, and poor prognosis, with median survival rarely exceeding 15–18 months. While standard treatments have modestly improved survival, novel strategies—such as immune modulation, targeted therapies, and adjunctive agents like vitamins—are under active investigation 6 8 10.

• Advances in surgical, radiotherapeutic, and chemotherapeutic techniques have incrementally improved outcomes, but significant breakthroughs are still needed 6 10.
• Resistance mechanisms, including the tumor’s unique microenvironment and ability to evade immune detection, hinder the effectiveness of conventional therapies 8.
• Immunotherapy and tumor microenvironment modulation are promising areas, with ongoing trials evaluating new combinations and adjuncts 8 10.
• The current niacin study seeks to address these challenges by enhancing immune response, representing a novel direction within a broader landscape of therapeutic innovation 8 10.

Are there risks or limitations to vitamin supplementation in brain cancer patients?

While some vitamins show potential as adjunctive therapies, the benefits of supplementation—especially at high doses—are not fully established, and safety concerns persist. The literature emphasizes the need for personalized approaches and rigorous clinical trials to determine efficacy and minimize risks 3 4 5 11.

• High-dose vitamin supplementation can cause adverse effects, and the net benefit may depend on cancer type, stage, and concurrent treatments 3 4 5.
• Large-scale reviews highlight the complexity of vitamin actions in cancer, with both pro- and antioxidant roles that may have context-dependent effects 4 5.
• Multivitamin use has not been linked to improved survival in glioblastoma, though specific supplements (e.g., vitamin D) may warrant further investigation 11.
• Personalized and medically supervised supplementation strategies are recommended, pending stronger clinical evidence 4.

Future Research Questions

The promising early results from the niacin trial underscore the need for larger, more definitive studies to clarify the role of vitamins in brain cancer therapy. Key areas for further investigation include the long-term safety and efficacy of vitamin supplementation, mechanisms of immune modulation, and identification of patient populations most likely to benefit.

Research Question	Relevance
What are the long-term effects and safety of high-dose vitamin B3 supplementation in glioblastoma patients?	Long-term safety data are lacking, and high-dose vitamin use may carry risks. Understanding adverse effects and sustained benefits is essential before widespread adoption 3 4 5.
How does vitamin B3 modulate immune cell function in the glioblastoma tumor microenvironment?	Mechanistic studies could clarify how niacin rejuvenates immune cells and whether this translates to improved clinical outcomes 4 5 8.
Which patient subgroups with glioblastoma are most likely to benefit from vitamin B3 adjunct therapy?	Glioblastoma is heterogeneous, and identifying biomarkers or clinical features that predict response could guide personalized therapy 8 10.
Can vitamin B3 or other vitamins improve overall survival when added to standard glioblastoma treatment?	While the current study focuses on progression-free survival, overall survival is a critical endpoint for future trials to assess true clinical benefit 1 3 11.
What are the optimal doses and administration schedules for vitamin B3 in combination with chemoradiotherapy?	Determining dosing regimens that maximize efficacy and minimize toxicity will inform future clinical practice and trial design 4 5 15.